Search research articles
Contact Us
Filters
Showing results (171-180 of 179) with videos related to
Page
of 18
Sort By:
You have reached the last page of results.
This site can display upto 179 results.
Nanotheranostics
|
January 9, 2020
Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy
Stefan J Roobol, Thomas A Hartjes, Johan A Slotman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 22, 2026
Phase 1 Dose-Escalation Study of [<sup>225</sup>Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
Sui Wai Ling, Mark Konijnenberg, Marcel Segbers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
Emmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Urologic Oncology
|
December 23, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with <sup>225</sup>Ac-PSMA-617 targeted alpha-radiation therapy
Maarten J van der Doelen, Niven Mehra, Inge M van Oort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2019
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Riad Ladjohounlou, Catherine Lozza, Alexandre Pichard, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 17, 2017
<sup>213</sup>Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts
Julie Nonnekens, Kristell L S Chatalic, Janneke D M Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 24, 2021
Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy
Valery Radchenko, Alfred Morgenstern, Amir R Jalilian, et al.
Prostate Cancer and Prostatic Diseases
|
July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
Bastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
The Lancet. Oncology
|
January 13, 2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Mike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, et al.
Page
of 18
Search research articles
Search
Showing results (171-180 of 179) with videos related to
Sort By:
Page
of 18
You have reached the last page of results.
This site can display upto 179 results.
Nanotheranostics
|
January 9, 2020
Uptake and subcellular distribution of radiolabeled polymersomes for radiotherapy
Stefan J Roobol, Thomas A Hartjes, Johan A Slotman, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 22, 2026
Phase 1 Dose-Escalation Study of [<sup>225</sup>Ac]Ac-PSMA I&T in Patients with Metastatic Castration-Resistant Prostate Cancer: An Analysis of Safety, Tolerability, and Dosimetry
Sui Wai Ling, Mark Konijnenberg, Marcel Segbers, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 21, 2018
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
Emmanuel Deshayes, Riad Ladjohounlou, Pierre Le Fur, et al.
Urologic Oncology
|
December 23, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with <sup>225</sup>Ac-PSMA-617 targeted alpha-radiation therapy
Maarten J van der Doelen, Niven Mehra, Inge M van Oort, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 8, 2019
Drugs That Modify Cholesterol Metabolism Alter the p38/JNK-Mediated Targeted and Nontargeted Response to Alpha and Auger Radioimmunotherapy
Riad Ladjohounlou, Catherine Lozza, Alexandre Pichard, et al.
Cancer Biotherapy & Radiopharmaceuticals
|
March 17, 2017
<sup>213</sup>Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts
Julie Nonnekens, Kristell L S Chatalic, Janneke D M Molkenboer-Kuenen, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
July 24, 2021
Production and Supply of α-Particle-Emitting Radionuclides for Targeted α-Therapy
Valery Radchenko, Alfred Morgenstern, Amir R Jalilian, et al.
Prostate Cancer and Prostatic Diseases
|
July 13, 2021
Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer
Bastiaan M Privé, Peter H J Slootbeek, Babette I Laarhuis, et al.
The Lancet. Oncology
|
January 13, 2024
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
Mike M Sathekge, Ismaheel O Lawal, Chandrasekhar Bal, et al.
Page
of 18